Geographical Factors in Diagnostic Delay among Multidrug Resistant Tuberculosis Patients

Authors

  • Nunuy Nuraeni Padjadjaran University image/svg+xml
  • Hendarsyah Suryadinata Department of Internal Medicine Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital Bandung
  • Bony Wiem Lestari Department of Public Health Faculty of Medicine, Universitas Padjadjaran

Keywords:

Diagnostic delay, multi-drug resistant tuberculosis, Xpert

Abstract

Background: Diagnostic delay is a  factor that can increase the high burden of multi-drug resistant tuberculosis (MDR-TB). Xpert Mycobacterium tuberculosis/Rifampicin known as Xpert is a rapid diagnostic test to detect MDR-TB. Diagnostic delay defined  the duration between a positive result of Acid Fast Bacilli (AFB) smear and positive result of MDR-TB by Xpert examination. This study aimed to compare the analysis of the geographical factors in the diagnostic delay of MDR-TB patients at Dr. Hasan Sadikin General Hospital as the top referral hospital in West Java Indonesia.

Methods: This study was conducted in the period July−December 2016 using cross sectional design. A total of 152 MDR-TB patient data were collected from medical records of MDR-TB patients registered in MDR-TB clinic at Dr. Hasan Sadikin General Hospital in the period 2015−2016.  The socio-demographic characteristics were collected and analyzed descriptively The diagnostic delay among MDR-TB patients was analyzed by Mann Whitney test.

Results: Diagnostic delay of MDR-TB patients was 15 days in median, with a minimal and maximal delay of 2−140 days. There was a significant difference of diagnostic delay between  patients from Bandung with a median of 9(2-135) days and patients from outside of Bandung with a median of 18(2-140) days, with p<0.01.

Conclusions: MDR-TB patients from outside Bandung have a longer diagnostic delay than patient from Bandung . A further expansion of using Xpert as a rapid diagnostic test for MDR-TB patient is needed.

References

WHO. Global Tuberculosis Report 2016. Geneva: World Health Organization; 2016. p. 12–4.

Piatek AS, Cleeff M, Alexander H, Coggin WL, Rehr M, Van Kampen S, et al. GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract. 2013;1(1):18–23.

Kementerian Kesehatan Republik Indonesia. Laporan Situasi Perkembangan TB MDR di Indonesia Triwulan II Tahun 2015. Jakarta: Kemenkes RI; 2016.

Niemz A, Boyle DS. Nucleic acid testing for tuberculosis at the point-of-care in highburden countries. Expert Rev Mol Diagn. 2012;12(7):687–701.

Van Kampen SC, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, et al. Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study. PLoS One. 2015;10(6):1–11.

WHO. Xpert MTB/RIF implementation manual: technical and operational “how-toâ€; practical considerations. Geneva: World Health Organization Press; 2014. p. 1–9.

Li Y, Ehiri J, Tang S, Li D, Bian Y, Lin H, et al. Factors associated with patient, and diagnostic delays in Chinese TB patients : a systematic review and meta-analysis. BMC Med. 2013;11(30):156–61.

Li Y, Ehiri J, Oren E, Hu D, Luo X, Liu Y, et al. Are we doing enough to stem the tide of acquired MDR-TB in countries with high TB burden? Results of a mixed method study in Chongqing, China. PLoS One. 2014;9(2):1–12.

Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara national regional state. Afr Health Sci. 2015;15(2):368–77.

Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Trop Med Int Health. 2015;20(11):1431–37.

Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis. 2015;15(1):461–7.

Elmi OS, Hasan H, Abdullah S, Zuki M, Jeab M, Alwi Z Bin, et al. Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries. 2015;9(10):1076–85.

Nair SA, Raizada N, Sachdeva KS. Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: a retrospective analysis. PLoS One. 2016;11(2):1–9.

Ullah I, Javaid A, Tahir Z, Ullah O, Shah AA. Pattern of drug resistance and risk factors associated with development of drug resistant mycobacterium tuberculosis in Pakistan. PLoS One. 2016;11(1):1–7.

Palomino JC, Martin A. Drug resistance mechanisms in mycobacterium tuberculosis. Antibiotics. 2014;3(3):317–40.

Downloads

Published

2017-09-29

Issue

Vol. 4 No. 3 (2017)

Section

Articles

License

  1. Authors retain copyright and grant Althea Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in Althea Medical Journal. Althea Medical Journal is licensed under CC BY-NC 4.0
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Althea Medical Journal.